Sustained polyp burden reduction with DUPIXENT 300 mg Q2W (SINUS-52)1,d

Illustrations of endoscopy adapted from actual patient images. Individual results may vary.

Reduction in bilateral Nasal Polyp score as early as Week 4, sustained through Week 521,a,b

aWeek 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -2.40 (95% CI: -2.77, -2.02) (-2.24 from a baseline score of 6.07 vs 0.15 from a baseline score of 5.96, respectively) (P<0.0001).1

bWeek 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -1.80 (95% CI: -2.10, -1.51) (-1.71 from a baseline score of 6.18 vs 0.10 from a baseline score of 5.96, respectively) (P<0.0001).1,2

cWeek 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.18 (95% CI: -1.47, -0.90) (-1.13 from a baseline score of 6.07 vs 0.05 from a baseline score of 5.96, respectively).1

dWeek 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.79 (95% CI: -2.13, -1.44) (-1.69 from a baseline score of 6.07 vs 0.09 from a baseline score of 5.96, respectively).1

Nasal polyp score (NPS), the sum of right and left nostril scores (range 0-4 for each nostril, range 0-8 in total) as evaluated by nasal endoscopy: reduced score indicates improvement.2

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.